BRPI0607140A2 - composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios - Google Patents

composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios

Info

Publication number
BRPI0607140A2
BRPI0607140A2 BRPI0607140-6A BRPI0607140A BRPI0607140A2 BR PI0607140 A2 BRPI0607140 A2 BR PI0607140A2 BR PI0607140 A BRPI0607140 A BR PI0607140A BR PI0607140 A2 BRPI0607140 A2 BR PI0607140A2
Authority
BR
Brazil
Prior art keywords
compound
cells
stimulating
carbohydrate
pharmaceutically acceptable
Prior art date
Application number
BRPI0607140-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Claude Coquelet
Charles Mioskowski
Alain Wagner
Original Assignee
Innodia Inc
Centre Nat Rech Scient Cnrs
Univ Pasteur Strasbourg I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innodia Inc, Centre Nat Rech Scient Cnrs, Univ Pasteur Strasbourg I filed Critical Innodia Inc
Publication of BRPI0607140A2 publication Critical patent/BRPI0607140A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
BRPI0607140-6A 2005-02-18 2006-02-17 composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios BRPI0607140A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65441305P 2005-02-18 2005-02-18
PCT/IB2006/001758 WO2006117696A2 (en) 2005-02-18 2006-02-17 Diastereoisomers of 4-hydroxyisoleucine and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0607140A2 true BRPI0607140A2 (pt) 2009-08-11

Family

ID=37086084

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607140-6A BRPI0607140A2 (pt) 2005-02-18 2006-02-17 composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios

Country Status (8)

Country Link
EP (1) EP1853552A2 (ja)
JP (1) JP2008530198A (ja)
CN (1) CN101128418A (ja)
AU (1) AU2006242851A1 (ja)
BR (1) BRPI0607140A2 (ja)
CA (1) CA2598491A1 (ja)
MX (1) MX2007009985A (ja)
WO (1) WO2006117696A2 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131836A2 (en) * 2005-03-22 2006-12-14 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
WO2008154743A1 (en) * 2007-06-19 2008-12-24 Innodia Inc. Methods for the synthesis of 4-hydroxyisoleucine, stereoisomers and analogs thereof
US20110136911A1 (en) * 2007-12-20 2011-06-09 The Feinstein Institute For Medical Research Treatment of sepsis and inhibition of mif by d-t4
JP6800968B2 (ja) 2015-10-23 2020-12-16 ナビター ファーマシューティカルズ， インコーポレイテッド セストリン−ｇａｔｏｒ２相互作用のモジュレーターおよびその使用
JP7179015B2 (ja) 2017-04-26 2022-11-28 ナビター ファーマシューティカルズ， インコーポレイテッド Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用
EP3870158A4 (en) 2018-10-24 2022-08-10 Navitor Pharmaceuticals, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
AU2020376950A1 (en) 2019-11-01 2022-06-09 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
CN112089710B (zh) * 2020-08-07 2022-04-01 郑州大学 4-羟基异亮氨酸在制备抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797767B1 (fr) * 1999-08-27 2002-06-14 Centre Nat Rech Scient Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
BRPI0415781A (pt) * 2003-10-27 2006-12-26 Innodia Inc método para o tratamento de diabetes em um paciente e kit farmacêutico
EP1657236A1 (en) * 2004-11-10 2006-05-17 Centre National De La Recherche Scientifique (Cnrs) Method for preparing diastereoisomers of 4-hydroxy isoleucine

Also Published As

Publication number Publication date
JP2008530198A (ja) 2008-08-07
WO2006117696A2 (en) 2006-11-09
CA2598491A1 (en) 2006-11-09
EP1853552A2 (en) 2007-11-14
AU2006242851A1 (en) 2006-11-09
WO2006117696A3 (en) 2007-01-25
MX2007009985A (es) 2008-03-11
CN101128418A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
BRPI0607156A2 (pt) composto, composição farmacêutica, uso do composto, kit farmacêutico, método para estimular a absorção de glicose por células de músculo e/ou célula de adipócito e método para estimular a secreção pancreática
BRPI0607140A2 (pt) composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios
AU2020201457B2 (en) Compositions and methods for managing or improving bone disorders, cartilage disorders, or both
KR102396831B1 (ko) 관절 건강을 위한 조성물 및 방법
Li et al. Antihyperglycemic and antihyperlipidemic action of cinnamaldehyde in C57BLKS/J db/db mice
Li et al. Gastrodin and isorhynchophylline synergistically inhibit MPP+-induced oxidative stress in SH-SY5Y cells by targeting ERK1/2 and GSK-3β pathways: involvement of Nrf2 nuclear translocation
ECSP088139A (es) Métodos para prevenir y tratar trastornos metabólicos y nuevos derivados de pirazol-o-glucósido
MX2010001696A (es) Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo.
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
BRPI0718596B8 (pt) composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
BRPI1015120A2 (pt) composto de lipídeo, composições farmacêutica e de lipídeo, métodos de produção de composto de lipídeo e para prevenir ou tratar doenças e usos de pelo menos um composto
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
NO20054408L (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
NZ589807A (en) Method for preventing and treating neurodegenerative diseases using a grape seed extract having less than 12% by weight galloylated proanthocyanidins
Wu et al. Anti-inflammatory effect of a polyphenol-enriched fraction from Acalypha wilkesiana on lipopolysaccharide-stimulated RAW 264.7 macrophages and acetaminophen-induced liver injury in mice
BRPI0611550A2 (pt) uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto
Chmiel-Perzyńska et al. Novel aspect of ketone action: β-hydroxybutyrate increases brain synthesis of kynurenic acid in vitro
BR112015001056A2 (pt) composto, composição farmacêutica, métodos para o tratamento de distúrbios mediados pela aldosterona, para o tratamento de doença ou uma condição, para o tratamento da síndrome metabólica, para o tratamento de uma doença fisiológica ou patológica e para o tratamento da doença renal crônica, insuficiência renal ou nefropatia diabética
Kulkarni et al. Antidiabetic potential of Rourea minor (Gaertn.) root in streptozotocin—induced diabetic rats
BRPI0602179A (pt) composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação
Yousaf et al. Hypolipidemic effect of extra virgin olive oil in diabetic rats
BR112021026561A2 (pt) Uso de uma composição farmacêutica na fabricação de um medicamento para a prevenção ou tratamento de doença hepática
Adhikari et al. Comparative evaluation of antidiabetic activity of fresh juice and ethanolic extract of Sunderban mangrove Rhizophora mucronata Lam. leaves in animal model
Selvakumar et al. Neurotoxicity associated with neuroleptic haloperidol induced tardive dyskinesia in Albino mice: Protective role of morin
US20230110065A1 (en) Combination of anethole trithione or its derivative, 4-oh-anethole trithione, with doxycycline or minocycline for the use thereof in the treatment of parkinson's disease

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired